117 related articles for article (PubMed ID: 12918099)
1. Study on the possibility of insulin as a carrier of IUdR for hepatocellular carcinoma-targeted therapy.
Ou XH; Kuang AR; Peng X; Zhong YG
World J Gastroenterol; 2003 Aug; 9(8):1675-8. PubMed ID: 12918099
[TBL] [Abstract][Full Text] [Related]
2. [Comparative studies on the banding characteristics of insulin receptor in human hepatocellular carcinoma and adjacent liver tissues].
Ou X; Kuang A; Liang Z; Cheng Z
Hua Xi Yi Ke Da Xue Xue Bao; 2002 Jan; 33(1):32-4. PubMed ID: 12599422
[TBL] [Abstract][Full Text] [Related]
3. [The binding characteristics of insulin-MTX to insulin receptor].
Ou X; Kuang A; Liang Z; Peng X; Zhong Y
Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):538-40. PubMed ID: 12528542
[TBL] [Abstract][Full Text] [Related]
4. Receptor binding characteristics and cytotoxicity of insulin-methotrexate.
Ou XH; Kuang AR; Liang ZL; Peng X; Zhong YG
World J Gastroenterol; 2004 Aug; 10(16):2430-3. PubMed ID: 15285037
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the combined effect of NIR laser and ionizing radiation on cellular damages induced by IUdR-loaded PLGA-coated Nano-graphene oxide.
Kargar S; Khoei S; Khoee S; Shirvalilou S; Mahdavi SR
Photodiagnosis Photodyn Ther; 2018 Mar; 21():91-97. PubMed ID: 29155336
[TBL] [Abstract][Full Text] [Related]
6. Use of radiolabelled iododeoxyuridine as adjuvant treatment for experimental tumours of the liver.
Zager JS; Delman KA; Ebright MI; Malhotra S; Larson S; Fong Y
Br J Surg; 2003 Oct; 90(10):1225-31. PubMed ID: 14515291
[TBL] [Abstract][Full Text] [Related]
7. Iododeoxyuridine uptake in proliferating smooth muscle cells in vitro.
Xu Y; Jagtap MR; Garland T; Ying J; McGarry RC; Mendonca MS; McLennan G
J Vasc Interv Radiol; 2007 Jan; 18(1 Pt 1):73-8. PubMed ID: 17296707
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled iododeoxyuridine: safety evaluation.
Harrison KA; Dalrymple GV; Baranowska-Kortylewicz J; Holdeman KP; Schneiderman MH; Lieberman RP; Sharp JG; Cohen SM; Leichner PK; Augustine SC; Tempero MA; Taylor RJ; Chiou RK
J Nucl Med; 1996 Apr; 37(4 Suppl):13S-16S. PubMed ID: 8676196
[TBL] [Abstract][Full Text] [Related]
9. Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.
Schulz CA; Mehta MP; Badie B; McGinn CJ; Robins HI; Hayes L; Chappell R; Volkman J; Binger K; Arzoomanian R; Simon K; Alberti D; Feierabend C; Tutsch KD; Kunugi KA; Wilding G; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1107-15. PubMed ID: 15234045
[TBL] [Abstract][Full Text] [Related]
10. PET imaging drug distribution after intratumoral injection: the case for (124)I-iododeoxyuridine in malignant gliomas.
Roelcke U; Hausmann O; Merlo A; Missimer J; Maguire RP; Freitag P; Radü EW; Weinreich R; Gratzl O; Leenders KL
J Nucl Med; 2002 Nov; 43(11):1444-51. PubMed ID: 12411546
[TBL] [Abstract][Full Text] [Related]
11. [Effect of inhibiting survivin expression with antisense oligodeoxynucleotides on sensitivity of hepatocellular carcinoma cell lines HepG2 and HepG2/ADM to adriamycin].
Dai DJ; Lu CD; Guo JM; Zhang J
Ai Zheng; 2005 Aug; 24(8):951-7. PubMed ID: 16086872
[TBL] [Abstract][Full Text] [Related]
12. Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver.
Macapinlac HA; Kemeny N; Daghighian F; Finn R; Zhang J; Humm J; Squire O; Larson SM
J Nucl Med; 1996 Apr; 37(4 Suppl):25S-29S. PubMed ID: 8676200
[TBL] [Abstract][Full Text] [Related]
13. Impact of IUdR on Rat 9L glioma cell survival for 25-35 keV photon-activated auger electron therapy.
Alvarez D; Hogstrom KR; Brown TA; Ii KL; Dugas JP; Ham K; Varnes ME
Radiat Res; 2014 Dec; 182(6):607-17. PubMed ID: 25409122
[TBL] [Abstract][Full Text] [Related]
14. Synthetic, implantable polymers for IUdR radiosensitization of experimental human malignant glioma.
Yuan X; Dillehay LE; Williams JR; Williams JA
Cancer Biother Radiopharm; 1999 Jun; 14(3):187-202. PubMed ID: 10850303
[TBL] [Abstract][Full Text] [Related]
15. [Significance of both nuclear and cytosol androgen receptor (AR) in assessment of AR status in prostate carcinoma and hepatocellular carcinoma].
Lu HP; Gao JH
Ai Zheng; 2003 Feb; 22(2):168-70. PubMed ID: 12600293
[TBL] [Abstract][Full Text] [Related]
16. Increased affinity of insulin for its receptor following conjugation to a second protein.
Huckett B; Ariatti M; Hawtrey A
Med Hypotheses; 1991 Oct; 36(2):135-9. PubMed ID: 1664037
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of insulin receptors and insulin action in human hepatoma cell line J-5.
Chuang LM; Lin BJ; Tai TY; Lee SC
Taiwan Yi Xue Hui Za Zhi; 1987 Nov; 86(11):1180-6. PubMed ID: 2450961
[No Abstract] [Full Text] [Related]
18. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
19. Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer.
Van den Abbeele AD; Tutrone RF; Berman RM; Baranowska-Kortylewicz J; Barclay PD; Richie JP; Adelstein SJ; Kassis AI
J Nucl Med; 1996 Feb; 37(2):315-20. PubMed ID: 8667069
[TBL] [Abstract][Full Text] [Related]
20. Receptor binding and biological potency of despentapeptide insulin.
Taylor R; Hetherington CS; Tolley S
Horm Metab Res; 1989 May; 21(5):249-52. PubMed ID: 2673959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
